Clinics, Labs and Data: How to Evaluate an Evidenced Healthcare Roll-Up
Completed acquisitions provide a basis for evaluating integration. Ownership, clinical workflow, data permissions and outcomes still require separate proof.
LongevityNext
Research Notes and Articles
Canine Longevity Drugs: What Conditional Approval Would—and Would Not—Establish
US animal-drug conditional approval has a defined evidentiary threshold. Sponsor milestones, a trial and market authorization remain different events.
The Health-Data Moat: Rights, Retention and the Cost of Useful Evidence
A framework for evaluating health-data rights, retention, collection costs and external performance without mistaking dataset size for defensibility.
Women’s Midlife Care: Where Capital Is Going—and What Clinical Evidence Supports
Dated care and product transactions reveal distinct business models. Symptom treatment, service performance and longevity claims require different evidence.
The Microbiome as a Hallmark of Aging: Association Is Not Yet an Intervention
Human associations and animal transfer experiments support different claims. Recent probiotic work adds a candidate mechanism, not established human geroprotection.
Longevity Clinic Registries: The Minimum Evidence Needed to Interpret Outcomes
A practical registry framework covering denominators, follow-up, comparisons, safety and governance—without treating participation as proof of efficacy.
Wearables as Aging Biomarkers: Prediction, Daily Variation and Clinical Use
Wearable signals can support large-scale age and risk models. Within-person change, external validity and decision usefulness remain separate tests.
Negative Longevity Trials: How to Read a Missed Endpoint Without Losing the Evidence
Missed primary endpoints constrain claims even when biomarkers or subgroups look promising. Three examples show why endpoint hierarchy and study context matter.
Rapamycin and Longevity: What Animal and Human Studies Separately Establish
Animal survival, authorised disease uses and human trials support different conclusions. Null endpoints and unresolved healthy-person longevity claims remain visible.
The Economics of a Longevity Clinic: An Auditable Operating Model
A transparent model for membership, clinical capacity, diagnostics, acquisition, retention, compliance and contribution—without invented industry margins.